Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „naltrexone“
Suchtreffer
Begriffe & Kennungen
Buvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenMysimba · 4.5 · Administration of naltrexone/bupropion to patients receiving either levodopa or amantadine concurrently should
Eintrag öffnenMysimba · 4.5 · Administration of naltrexone/bupropion with inhibitors or inducers of UGT 1A2 and 2B7 should be undertaken wit
Eintrag öffnenMysimba · 4.5 · CYP2D6 substrates In a clinical study, naltrexone/bupropion (32 mg naltrexone hydrochloride /360 mg bupropion
Eintrag öffnenMysimba · 4.5 · Caution should be used when prescribing naltrexone/bupropion to patients with predisposing factors that may in
Eintrag öffnenMysimba · 4.5 · Coadministration of naltrexone/bupropion with digoxin may decrease plasma digoxin levels. Monitor plasma digox
Eintrag öffnenMysimba · 4.5 · Naltrexone/bupropion has not been studied in conjunction with alpha-adrenergic blockers or clonidine.
Eintrag öffnenMysimba · 4.5 · Naltrexone/bupropion is contraindicated in patients receiving concomitant treatment with monoamine oxidase inh
Eintrag öffnenMysimba · 4.5 · Naltrexone/bupropion should preferably be taken with food, as it is known that both naltrexone and bupropion p
Eintrag öffnenMysimba · 4.5 · Opioids Naltrexone/bupropion is contraindicated in patients currently dependent on opioids including opioid- c
Eintrag öffnenMysimba · 4.5 · Since bupropion is extensively metabolised, caution is advised when naltrexone/bupropion is co-administered wi
Eintrag öffnenMysimba · 4.5 · Since bupropion is extensively metabolised, caution is advised when naltrexone/bupropion is co-administered wi
Eintrag öffnenMysimba · 4.8 · Gastrointestinal adverse reactions The vast majority of subjects treated with naltrexone/bupropion who experie
Eintrag öffnenMysimba · 4.8 · In clinical studies, 23.8% of subjects receiving naltrexone/bupropion and 11.9% of subjects receiving placebo
Eintrag öffnenMysimba · 4.8 · Other frequent adverse reactions The majority of subjects treated with naltrexone/bupropion who reported dizzi
Eintrag öffnenMysimba · 4.8 · Seizures The incidence of seizure in naltrexone/bupropion over the course of the clinical program was 0.06% (2
Eintrag öffnenMysimba · 4.8 · Table 1. Adverse reactions reported in subjects who received naltrexone/bupropion as a fixed- dose combination
Eintrag öffnenMysimba · 4.8 · Table 2. Adverse reactions of the individual components naltrexone and bupropion identified in the respective
Eintrag öffnenMysimba · 4.8 · The safety profile of naltrexone/bupropion (NB) summarised in Table 1 below is based on clinical studies perfo
Eintrag öffnen